Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease

被引:36
作者
Paillé, V
Brachet, P
Damier, P
机构
[1] CHU Nantes, INSERM, U437, F-44093 Nantes, France
[2] CHU Nantes, Neurol Clin, F-44035 Nantes 01, France
[3] CHU Nantes, Ctr Invest Clin, F-44035 Nantes 01, France
关键词
behavior; dyskinesias; levodopa; 6-OHDA; Parkinson's disease;
D O I
10.1097/00001756-200403010-00035
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias. We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.
引用
收藏
页码:561 / 564
页数:4
相关论文
共 50 条
  • [31] Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease
    Carlsson, Thomas
    Carta, Manolo
    Winkler, Christian
    Bjorklund, Anders
    Kirik, Deniz
    JOURNAL OF NEUROSCIENCE, 2007, 27 (30) : 8011 - 8022
  • [32] Triptolide Protects Dopaminergic Neurons from 6-OHDA Lesion in a Rat Model of Parkinson's Disease
    Zhang, Wenjing
    An, Haiting
    Zhang, Feilong
    Dong, Lin
    Wang, Qi
    Su, Ruijun
    Qian, Yanjing
    Gong, Xiaoli
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2015, 11 (01) : 10 - 18
  • [33] Genetic predisposition plays a role in nigral cell death in Parkinson's disease
    Kurth, MC
    Kurth, JH
    PARKINSONISM & RELATED DISORDERS, 1999, 5 (04) : 169 - 172
  • [34] Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias
    Camila Marchioni
    Bruno Lopes Santos-Lobato
    Maria Eugênia Costa Queiroz
    José Alexandre S. Crippa
    Vitor Tumas
    Journal of Neural Transmission, 2020, 127 : 1359 - 1367
  • [35] Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias
    Marchioni, Camila
    Santos-Lobato, Bruno Lopes
    Costa Queiroz, Maria Eugenia
    Crippa, Jose Alexandre S.
    Tumas, Vitor
    JOURNAL OF NEURAL TRANSMISSION, 2020, 127 (10) : 1359 - 1367
  • [36] Preliminary Investigation of Risk Factors Causing Dyskinesias in Parkinson's Disease in South Africa
    Gaida, Razia
    Truter, Ilse
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2014, 13 (08) : 1353 - 1359
  • [37] Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease
    Deogaonkar, M
    Subramanian, T
    BRAIN RESEARCH REVIEWS, 2005, 50 (01) : 156 - 168
  • [38] Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease
    Pisano, Clarissa A.
    Brugnoli, Alberto
    Novello, Salvatore
    Caccia, Carla
    Keywood, Charlotte
    Melloni, Elsa
    Vailati, Silvia
    Padoani, Gloria
    Morari, Michele
    NEUROPHARMACOLOGY, 2020, 167
  • [39] Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective
    Hagell, P
    Cenci, MA
    BRAIN RESEARCH BULLETIN, 2005, 68 (1-2) : 4 - 15
  • [40] Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease
    Hoff, JI
    vander Plas, AA
    Wagemans, EAH
    van Hilten, JJ
    MOVEMENT DISORDERS, 2001, 16 (01) : 58 - 61